尤瑞克林聯合曲克蘆丁腦蛋白水解物對急性腦梗死患者凝血功能及神經功能的影響

楊長路　荊艷

摘要：目的 ?研究尤瑞克林聯合曲克蘆丁腦蛋白水解物對急性腦梗死患者凝血功能及神經功能的影響。方法 ?選取2018年5月～2019年5月在我院診治的124例急性腦梗死患者為研究對象，采用隨機數字表法分為對照組和觀察組，各62例。對照組采用尤瑞克林治療，觀察組在對照組基礎上聯合曲克蘆丁腦蛋白水解物治療，比較兩組臨床治療總有效率、治療前后凝血功能指標（血小板計數、纖維蛋白原、D-二聚體）、神經功能缺損評分及臨床不良反應發生情況。結果 ?觀察組臨床治療總有效率為91.93%，高于對照組的80.64%（P<0.05）;治療后兩組血小板計數、纖維蛋白原、D-二聚體均低于治療前，且觀察組低于對照組（P<0.05）;治療后兩組神經功能缺損評分均低于治療前，且觀察組低于對照組（P<0.05）;觀察組臨床不良反應發生率為3.22%，與對照組的4.83%比較，差異無統計學意義（P>0.05）。結論 ?尤瑞克林聯合曲克蘆丁腦蛋白水解物可改善急性腦梗死患者凝血功能，促進神經功能恢復，提高臨床治療總有效率，且臨床不良反應少。

關鍵詞：尤瑞克林;腦蛋白水解物;急性腦梗死;凝血功能;神經功能

中圖分類號：R972 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 文獻標識碼：A ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? DOI：10.3969/j.issn.1006-1959.2020.18.050

文章編號：1006-1959（2020）18-0150-02

Effect of UrinaryKallindinogenase Combined with Troxerutin and Cerebroprotein Hydrolysate

on Blood Coagulation and Nerve Function in Patients with Acute Cerebral Infarction

YANG Chang-lu，JING Yan

（Department of Neurology，Tianjin Permanent Hospital，Tianjin 300450，China）

Abstract：Objective ?To study the effect of UrinaryKallindinogenase combined with troxerutin and cerebroprotein hydrolysate on blood coagulation and nerve function in patients with acute cerebral infarction.Methods ?A total of 124 patients with acute cerebral infarction who were diagnosed and treated in our hospital from May 2018 to May 2019 were selected as the research objects. They were divided into a control group and an observation group by a random number table method， with 62 cases in each group. The control group was treated with UrinaryKallindinogenase， and the observation group was combined with troxerutin and cerebroprotein hydrolysate on the basis of the control group. The total effective rate of clinical treatment and the coagulation function indexes （platelet count， fibrinogen， D -Dimer）， neurological deficit score and clinical adverse reactions.Results ?The total effective rate of clinical treatment in the observation group was 91.93%， which was higher than 80.64% in the control group（P<0.05）;After treatment， the platelet count， fibrinogen， and D-dimer of the two groups were lower than before treatment， and the observation group was lower than the control group（P<0.05）; after treatment， the scores of neurological deficits in both groups were Lower than before treatment， and the observation group was lower than the control group（P<0.05）; the clinical adverse reaction rate of the observation group was 3.22%， compared with 4.83% in the control group， the difference was not statistically significant （P>0.05）.Conclusion ?UrinaryKallindinogenase combined with troxerutin and cerebroprotein hydrolysate could improve the coagulation function of patients with acute cerebral infarction， promote the recovery of nerve function， improve the total effective rate of clinical treatment， and had fewer clinical adverse reactions.

Key words：UrinaryKallindinogenase;Cerebroprotein hydrolysate;Acute cerebral infarction;Coagulation function;Neural function

急性腦梗死（acute cerebral infarction）具有發病急、病情進展快等特點，會對患者造成不同程度神經功能損傷。臨床常規給予補液、抗凝、溶栓、改善微循環治療以減輕患者臨床癥狀。尤瑞克林屬于擴張血管、改善微循環灌注藥物，可保護腦神經，促進神經功能缺損恢復。研究顯示[1]，在常規治療的基礎上聯合使用神經保護或神經改善藥物，可以改善腦梗死的治療效果。曲克蘆丁腦蛋白水解物注射液屬于改善神經功能藥物，對改善微循環具有一定作用。目前，關于神經保護藥物聯合應用治療療效、安全性等研究較少，且已有研究存在爭議。……